Trial Condition(s):
Hemophilia A
Assessing Physician and Hemophilia A Patient Reasons and Expectations for Switching Treatment to Kovaltry & Jivi: A Nested Study within an Existing Registry
Bayer Identifier:
19866
ClinicalTrials.gov Identifier:
EudraCT Number:
Not Available
EU CT Number:
Not Available
Trial Purpose
This US study aims to assess hemophilia A patient characteristics and reasons for switching from both patient/caregiver and physician perspectives. For this purpose, this research study will include hemophilia A patients who have switched from an existing therapy to Kovaltry or Jivi. In doing so, real world evidence will be obtained from both patient and physician perspectives offering key insights for effective therapeutic management of patients with hemophilia A and to more fully understand what drives patient switching from a patient perspective and a physician perspective.
Inclusion Criteria
No Inclusion Criteria Available
Exclusion Criteria
No Exclusion Criteria Available
Trial Summary
Enrollment Goal
Trial Dates
Phase
Could I receive a placebo?
Products
Accepts Healthy Volunteers
Where to Participate
| Locations | |
|---|---|
Locations Yale Hemophilia Treatment Center New Haven, United States, 06510 | Contact Us: E-mail: [email protected] Phone: (+)1-888-84 22937 |
Locations Maine Hemophilia and Thrombosis Center Scarborough, United States, 04074 | Contact Us: E-mail: [email protected] Phone: (+)1-888-84 22937 |
Locations Dartmouth-Hitchcock Comprehensive Hemophilia and Thrombosis Center Lebanon, United States, 03756 | Contact Us: E-mail: [email protected] Phone: (+)1-888-84 22937 |
Locations Boston Hemophilia Center at Children's Hospital of Boston/Brigham Women's Boston, United States, 02115 | Contact Us: E-mail: [email protected] Phone: (+)1-888-84 22937 |
Locations Children's Hospital of Philadelphia (CHOP) Philadelphia, United States, 01914 | Contact Us: E-mail: [email protected] Phone: (+)1-888-84 22937 |
Locations Weill Cornell Medicine New York, United States, 10065 | Contact Us: E-mail: [email protected] Phone: (+)1-888-84 22937 |
Locations Mary M. Gooley Hemophilia Center, Inc. Rochester, United States, 14621 | Contact Us: E-mail: [email protected] Phone: (+)1-888-84 22937 |
Locations Children's National Medical Center Washington, United States, 20010 | Contact Us: E-mail: [email protected] Phone: (+)1-888-84 22937 |
Locations Hemophilia Center of Western Pennsylvania Pittsburgh, United States, 15213 | Contact Us: E-mail: [email protected] Phone: (+)1-888-84 22937 |
Locations The Johns Hopkins University Hemophilia Treatment Center Baltimore, United States, 21205 | Contact Us: E-mail: [email protected] Phone: (+)1-888-84 22937 |
Locations Penn Comprehensive Hemophilia and Thrombophilia Program / Hospital UPENN Philadelphia, United States, 19104 | Contact Us: E-mail: [email protected] Phone: (+)1-888-84 22937 |
Locations St. Jude Children's Research Hospital Memphis, United States, 38105 | Contact Us: E-mail: [email protected] Phone: (+)1-888-84 22937 |
Locations St. Josephs Hemophilia Treatment Center Tampa, United States, 33607 | Contact Us: E-mail: [email protected] Phone: (+)1-888-84 22937 |
Locations Emory / Children's Healthcare of Atlanta Atlanta, United States, 30322 | Contact Us: E-mail: [email protected] Phone: (+)1-888-84 22937 |
Locations Johns Hopkins All Children's Hospital St. Petersburgh, United States, 33701 | Contact Us: E-mail: [email protected] Phone: (+)1-888-84 22937 |
Locations Indiana Hemophilia and Thrombosis Center IHTC Indianapolis, United States, 46260 | Contact Us: E-mail: [email protected] Phone: (+)1-888-84 22937 |
Locations Michigan State University Center for Bleeding Disorders & Clotting Disorders East Lansing, United States, 48824 | Contact Us: E-mail: [email protected] Phone: (+)1-888-84 22937 |
Locations Univ of Michigan Hemophilia and Coagulation Disorders Ann Arbor, United States, 48109 | Contact Us: E-mail: [email protected] Phone: (+)1-888-84 22937 |
Locations Bleeding and Clotting Disorders Institute Peoria, United States, 61615 | Contact Us: E-mail: [email protected] Phone: (+)1-888-84 22937 |
Locations Blood Center of Wisconsin, Inc. /Childrens Hosp of Wisconsin Milwaukee, United States, 53226 | Contact Us: E-mail: [email protected] Phone: (+)1-888-84 22937 |
Locations Louisiana Center for Bleeding and Clotting Disorders / Tulane New Orleans, United States, 70112 | Contact Us: E-mail: [email protected] Phone: (+)1-888-84 22937 |
Locations UT Southwestern/Children's Health Dallas Dallas, United States, 75390 | Contact Us: E-mail: [email protected] Phone: (+)1-888-84 22937 |
Locations Children's Mercy Hospital (Kansas City) Kansas City, United States, 64108 | Contact Us: E-mail: [email protected] Phone: (+)1-888-84 22937 |
Locations University of Colorado Denver Hemophilia and Thrombosis Center Aurora, United States, 80045 | Contact Us: E-mail: [email protected] Phone: (+)1-888-84 22937 |
Locations University of California, San Diego La Jolla, United States, 92093 | Contact Us: E-mail: [email protected] Phone: (+)1-888-84 22937 |
Locations BloodWorks (Puget Sound) Seattle, United States, 98104 | Contact Us: E-mail: [email protected] Phone: (+)1-888-84 22937 |
Locations Oregon Health & Science University Portland, United States, 97239 | Contact Us: E-mail: [email protected] Phone: (+)1-888-84 22937 |
Trial Design
Assessing Hemophilia A Patient and Physician Reasons and Expectations for Switching Treatment to Kovaltry & Jivi: A Nested Study within an Existing Registry
Trial Type:
Observational
Intervention Type:
Drug
Trial Purpose:
N/A
Allocation:
N/A
Blinding:
N/A
Assignment:
N/A
Trial Arms:
2
Primary Outcome
- Patient reported reasons for switching FVIII replacement treatment to Kovaltry or Jivi using a Bayer designed surveyData from consenting patients will be collected by ATHNTimeframe: Up to 4 years
- Patient expectations of switching FVIII replacement therapy to Kovaltry or Jivi would affect lifestyle/quality of life using a Bayer designed surveyData from consenting patients will be collected by ATHNTimeframe: Up to 4 years
- Patient expectations when adjusting to the new product after switch using a Bayer designed surveyData from consenting patients will be collected by ATHNTimeframe: Up to 4 years
- Patient reported root of expectations using a Bayer designed surveyData from consenting patients will be collected by ATHNTimeframe: Up to 4 years
- Patient reported reasons that would deter them from switching FVIII replacement products using a Bayer designed surveyData from consenting patients will be collected by ATHNTimeframe: Up to 4 years
- Physicians reported discipline using a Bayer designed surveyData from consenting patients will be collected by ATHNTimeframe: Up to 4 years
- Physicians reported reasons for switching FVIII replacement treatment to Kovaltry or Jivi using a Bayer designed surveyData from consenting patients will be collected by ATHNTimeframe: Up to 4 years
- Dosing Regimen (pre/post-switch)Data from consenting patients will be collected by ATHNTimeframe: Up to 4 years
- Physicians reported reason of newly selected dose/dosing interval using a Bayer designed surveyData from consenting patients will be collected by ATHNTimeframe: Up to 4 years
- Physicians reported rationale base for new dosing regimen selection using a Bayer designed surveyData from consenting patients will be collected by ATHNTimeframe: Up to 4 years
- Physicians reported communication about adjustment period when switching using a Bayer designed surveyData from consenting patients will be collected by ATHNTimeframe: Up to 4 years
- Physicians reported reasons that a provider would not encourage a patient to switch FVIII products using a Bayer designed surveyData from consenting patients will be collected by ATHNTimeframe: Up to 4 years
Additional Information
Copyright © Bayer
Powered by
